Skip to main content
Tourmaline Bio, Inc. logo

Tourmaline Bio, Inc. — Investor Relations & Filings

Ticker · TRML ISIN · US87410C1045 US Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2023-10-10 Regulatory Filings
Country US United States of America
Listing US TRML

About Tourmaline Bio, Inc.

https://www.tourmalinebio.com/

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for patients with life-altering inflammatory and immune diseases. The company's lead asset is pacibekitug, a monoclonal antibody that targets the interleukin-6 (IL-6) cytokine, a key driver of inflammation. Pacibekitug is being developed as a potential treatment for a range of conditions, with a primary focus on atherosclerotic cardiovascular disease (ASCVD) and other severe autoimmune and inflammatory disorders, aiming to establish a new standard of care in areas with high unmet medical need.

Recent filings

Filing Released Lang Actions
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A (Amendment No. 1) filed with the SEC, which is a current report amendment. It amends a previously filed Form 8-K related to a merger agreement and provides supplemental disclosures to a proxy statement. The document discusses merger details, litigation matters, and valuation analyses related to the merger. It is not a full annual or quarterly report, nor is it a proxy solicitation or voting results announcement. It is an amendment to a current report, which is a regulatory filing. The document is lengthy (15,000 characters) and contains substantive information, but it is not a financial report like 10-K or IR. It is best classified as a Regulatory Filing (RNS) because it is an SEC current report amendment providing updates and corrections related to merger disclosures and litigation, which do not fit other specific categories.
2023-10-10 English
8-K
Notice of Dividend Amount Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Talaris Therapeutics, Inc. It announces a special cash dividend declaration in connection with a merger agreement and provides details about the merger and dividend. The document includes a press release as an exhibit and discusses forward-looking statements and solicitation materials related to the merger. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is primarily an announcement of a corporate event (special dividend declaration tied to a merger) and related disclosures. The document is not a proxy statement, merger filing, or earnings release. Given the nature of the content—announcement of a special dividend and merger-related update—the most appropriate classification is Notice of Dividend Amount (DIV).
2023-10-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Talaris Therapeutics, Inc. It includes disclosures about a merger agreement, litigation matters related to the merger, supplemental disclosures to a proxy statement, and financial projections related to the merger transaction. The document references the Proxy Statement and amendments thereto, but it is not the Proxy Statement itself. It also discusses legal proceedings and settlement agreements. The filing is primarily an update on merger-related events, legal matters, and supplemental disclosures rather than a full financial report, earnings release, or proxy solicitation. The presence of detailed merger-related disclosures and supplemental information to the Proxy Statement indicates this is a regulatory filing providing material event updates. It does not fit the categories of Annual Report, Interim Report, Proxy Solicitation, or Merger & Acquisition filings directly, as it is a current report (8-K) with merger and litigation updates. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not neatly fit other categories.
2023-10-06 English
425 Filing
Legal Proceedings Report Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates by a company. The text includes detailed disclosures about a merger agreement, litigation matters, supplemental disclosures to a proxy statement, and financial projections related to the merger. It references the Proxy Statement and supplemental disclosures but does not itself constitute the proxy statement or a full merger filing. The document is lengthy (15,000 characters) and contains substantive information about legal proceedings and merger-related updates. The presence of detailed litigation updates and merger-related disclosures aligns with a Legal Proceedings Report (LTR) rather than a pure merger filing (MA) or proxy solicitation (PSI). It is not an announcement of a report publication (RPA) nor a certification or attestation (RNS). Therefore, the best classification is Legal Proceedings Report (LTR).
2023-10-06 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Talaris Therapeutics, Inc. It primarily provides an update on a merger agreement and includes an investor presentation as an exhibit. The text explicitly states that the exhibit is an investor presentation used in meetings with investors and analysts. The document does not contain detailed financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). It also does not fit categories like Merger & Acquisition filings (MA) or Proxy Solicitation (PSI) since it is a current report furnishing information about the merger and includes an investor presentation. The presence of an investor presentation as an exhibit and the nature of the update aligns best with the Investor Presentation (IP) category. The document length (over 12,000 characters) and content confirm it is not a brief announcement or certification, so it is not RPA or RNS. Therefore, the filing type is Investor Presentation (IP) with high confidence.
2023-09-26 English
425 Filing
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC by Talaris Therapeutics, Inc. It reports on a merger agreement and includes an investor presentation as an exhibit. The text references Rule 425 communications, which are related to merger communications and investor presentations. The document is not a full financial report but a current report disclosing material events, specifically merger-related updates and an investor presentation. It also explicitly states that the investor presentation is attached as an exhibit and is being furnished, not filed as a formal report. The document does not contain detailed financial statements or comprehensive financial analysis but rather updates and presentation materials related to the merger. Therefore, the most appropriate classification is Investor Presentation (IP).
2023-09-26 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.